 CAMBRIDGE, Mass., Feb. 08, 2022 GLOBE NEWSWIRE -- Werewolf Therapeutics, Inc. the Company or Werewolf Nasdaq: HOWL, an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the bodys immune system for the treatment of cancer, today announced that management will present at the SVB Leerink Global Healthcare Conference taking place virtually from February 14-18, 2022. 